Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Renal transplantation].

Ryohei Hattori1, Yoshinari Ono, Shinichi Oshima

  • 1Department of Urology, Nagoya University, Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[PELVIC ORGAN PROLAPSE AND INGUINAL HERNIA AGGRAVATED BY OVARIAN FIBROTHECOMA WITH ASCITES].

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology·2022
Same author

Impact of Histological Variants on Clinical Responses to Pembrolizumab in Patients With Metastatic Urothelial Cancer.

Anticancer research·2022
Same author

Hyperammonemic encephalopathy associated with post-radiotherapy vesicointestinal fistula following cervical cancer.

The journal of obstetrics and gynaecology research·2021
Same author

Drug-induced cystitis caused by herbal medicine (Bofutsushosan).

Urology case reports·2021
Same author

pT3 subclassification of renal pelvic cancer considering the tumor location improves the patients' prognostic accuracy.

Virchows Archiv : an international journal of pathology·2021
Same author

Grade group 2 (10% ≥ GP4) patients have very similar malignant potential with grade group 1 patients, given the risk of intraductal carcinoma of the prostate.

International journal of clinical oncology·2021

New immunosuppressive drugs and protocols improve kidney transplant outcomes by reducing rejection. Advancements allow for increased use of unrelated or ABO incompatible living donors, enhancing transplant accessibility.

Area of Science:

  • Immunology
  • Nephrology
  • Transplantation Medicine

Context:

  • Kidney transplantation is a vital treatment for end-stage renal disease.
  • Acute allograft rejection remains a significant challenge in kidney transplant recipients.
  • Recent advancements in immunosuppressive therapies have improved graft survival rates.

Purpose:

  • To review current and emerging immunosuppressive agents for kidney transplantation.
  • To discuss novel immunosuppressive protocols, including steroid or calcineurin inhibitor withdrawal.
  • To highlight the impact of these advancements on expanding donor pool options.

Summary:

  • Established immunosuppressants like mycophenolate mofetil, basiliximab, and calcineurin inhibitors have significantly reduced acute rejection.

Related Experiment Videos

  • Newly developed agents including CTLA4-Ig, LEA29Y, rituximab, and FTY720 offer further therapeutic potential.
  • Immunosuppressive strategies are evolving, with protocols exploring the withdrawal of steroids or calcineurin inhibitors.

    • Impact:

    • These advancements facilitate an increase in kidney transplants from unrelated or ABO incompatible living donors.
    • Improved immunosuppression broadens eligibility for transplantation, potentially reducing waitlist times.
    • Enhanced protocols contribute to better long-term graft function and patient survival in kidney transplant recipients.